Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 42 results.
User Information
Export Records
  1. 1.   Clinical Trial Assessment of Infrastructure Matrix Tool to Improve the Quality of Research Conduct in the Community
  2. Dimond, E. P.; Zon, R. T.; Weiner, B. J.; St Germain, D.; Denicoff, A. M.; Dempsey, K.; Carrigan, A. C.; Teal, R. W.; Good, M. J.; McCaskill-Stevens, W.; Grubbs, S. S.; Dimond, E. P.; Zon, R. T.; Weiner, B. J.; St Germain, D.; Denicoff, A. M.; Dempsey, K.; Carrigan, A. C.; Teal, R. W.; Good, M. J.; McCaskill-Stevens, W.; Grubbs, S. S.
  3. Journal of Oncology Practice. 2016, Jan; 12(1): 63-4, e23-35.
  1. 2.   Connecting chemosensitivity, gene expression and disease
  2. Covell, D. G.
  3. Trends in Pharmacological Sciences. 2008 29(1): 1-5.
  1. 3.   The NCI60 human tumour cell line anticancer drug screen
  2. Shoemaker, R. H.
  3. Nature Reviews Cancer. 2006, Oct; 6(10): 813-823.
  1. 4.   Mining the NCI antiviral compounds for HIV-1 integrase inhibitors
  2. Deng, J. X.; Kelley, J. A.; Barchi, J. J.; Sanchez, T.; Dayam, R.; Pommier, Y.; Neamati, N.
  3. Bioorganic & Medicinal Chemistry. 2006, JUN 1; 14(11): 3785-3792.
  1. 5.   Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen
  2. Huang, R.; Wallqvist, A.; Covell, D. G.
  3. Genomics. 2006, MAR; 87(3): 315-328.
  1. 6.   Evaluating chemical structure similarity as an indicator of cellular growth inhibition
  2. Wallqvist, A.; Huang, R. L.; Thanki, N.; Covell, D. G.
  3. Journal of Chemical Information and Modeling. 2006, JAN-FEB; 46(1): 430-437.
  1. 7.   Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action
  2. Huan, R.; Wallqvist, A.; Thanki, N.; Covell, D.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9069S-9069S.
  1. 8.   Antitumor activity and distribution of pyrroloiminoquinones in the sponge genus Zyzzya
  2. Dijoux, M. G.; Schnabel, P. C.; Hallock, Y. F.; Boswell, J. L.; Johnson, T. R.; Wilson, J. A.; Irel, C. M.; van Soest, R.; Boyd, M. R.; Barrows, L. R.; Cardellina, J. H.
  3. Bioorganic & Medicinal Chemistry. 2005, NOV 1; 13(21): 6035-6044.
  1. 9.   Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells
  2. Wallqvist, A.; Huang, R.; Covell, D. G.; Roschke, A. V.; Gelhaus, K. S.; Kirsch, I. R.
  3. Molecular Cancer Therapeutics. 2005, OCT; 4(10): 1559-1568.
  1. 10.   Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity
  2. Kong, D. H.; Park, E. J.; Stephen, A. G.; Calvani, M.; Cardellina, J. H.; Monks, A.; Fisher, R. J.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2005, OCT 1; 65(19): 9047-9055.
  1. 11.   Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical Cushing syndrome: A clinical and molecular genetic investigation
  2. Matyakhina, L.; Freedman, R. J.; Bourdeau, I.; Wei, M. H.; Stergiopoulos, S. G.; Chidakel, A.; Walther, M.; bu-Asab, M.; Tsokos, M.; Keil, M.; Toro, J.; Linehan, W. M.; Stratakis, C. A.
  3. Journal of Clinical Endocrinology & Metabolism. 2005, JUN; 90(6): 3773-3779.
  1. 12.   A high-throughput fluorescence-anisotropy screen that identifies small molecule inhibitors of the DNA binding of B-ZIP transcription factors
  2. Rishi, V.; Potter, T.; Laudeman, J.; Reinhart, R.; Silvers, T.; Selby, M.; Stevenson, T.; Krosky, P.; Stephen, A. G.; Acharya, A.; Moll, J.; Oh, W. J.; Scudiero, D.; Shoemaker, R. H.; Vinson, C.
  3. Analytical Biochemistry. 2005, MAY 15; 340(2): 259-271.
  1. 13.   Elucidation of thioredoxin as a molecular target for antitumor quinols
  2. Bradshaw, T. D.; Matthews, C. S.; Cookson, J.; Chew, E. H.; Shah, M.; Bailey, K.; Monks, A.; Harris, E.; Westwell, A. D.; Wells, G.; Laughton, C. A.; Stevens, M. F. G.
  3. Cancer Research. 2005, MAY 1; 65(9): 3911-3919.
  1. 14.   Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations
  2. Johnston, E.; Dupnik, K. M.; Gonzales, M. J.; Winters, M. A.; Rhee, S. Y.; Imamichi, T.; Shafer, R. W.
  3. Aids. 2005, APR 29; 19(7): 731-733.
  1. 15.   Synthesis of nonracemic 3-deoxyschweinfurthin B
  2. Neighbors, J. D.; Beutler, J. A.; Wiemer, D. F.
  3. Journal of Organic Chemistry. 2005, FEB 4; 70(3): 925-931.
  1. 16.   Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones
  2. Budihas, S. R.; Gorshkova, I.; Gaidamakov, S.; Wamiru, A.; Bona, M. K.; Parniak, M. A.; Crouch, R. J.; McMahon, J. B.; Beutler, J. A.; Le Grice, S. F. J.
  3. Nucleic Acids Research. 2005 33(4): 1249-1256.
  1. 17.   Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action
  2. Huang, R.; Wallqvist, A.; Thanki, N.; Covell, D. G.
  3. Pharmacogenomics Journal. 2005 5(6): 381-399.
  1. 18.   Anticancer metal compounds in NCI's tumor-screening database: putative mode of action
  2. Huang, R. L.; Wallqvist, A.; Covell, D. G.
  3. Biochemical Pharmacology. 2005 69(7): 1009-1039.
  1. 19.   Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel
  2. Svingen, P. A.; Loegering, D.; Rodriquez, J.; Meng, X. W.; Mesner, P. W.; Holbeck, S.; Monks, A.; Krajewski, S.; Scudiero, D. A.; Sausville, E. A.; Reed, J. C.; Lazebnik, Y. A.; Kaufmann, S. H.
  3. Clinical Cancer Research. 2004, OCT 15; 10(20): 6807-6820.
  1. 20.   Structure-based discovery of nonpeptidic small organic compounds to block the T cell response to myelin basic protein
  2. Koehler, N. K. U.; Yang, C. Y.; Varady, J.; Lu, Y. P.; Wu, X. W.; Liu, M.; Yin, D. X.; Bartels, M.; Xu, B. Y.; Roller, P. P.; Long, Y. Q.; Li, P.; Kattah, M.; Cohn, M. L.; Moran, K.; Tilley, E.; Richert, J. R.; Wang, S. M.
  3. Journal of Medicinal Chemistry. 2004, OCT 7; 47(21): 4989-4997.
  1. 21.   Classification of proliferative pulmonary lesions of the mouse: Recommendations of the mouse models of human cancers consortium
  2. Nikitin, A. Y.; Alcaraz, A.; Anver, M. R.; Bonson, R. T.; Cardiff, R. D.; Dixon, D.; Fraire, A. E.; Gabrielson, E. W.; Gunning, W. T.; Haines, D. C.; Kaufman, M. H.; Linnoila, R. I.; Maronpot, R. R.; Rabson, A. S.; Reddick, R. L.; Rehm, S.; Rozengurt, N.; Schuller, H. M.; Shmidt, E. N.; Travis, W. D.; Ward, J. M.; Jacks, T.
  3. Cancer Research. 2004 64(7): 2307-2316.
  1. 22.   Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the bar harbor meeting of the mouse models of human cancer consortium prostate pathology committee
  2. Shappell, S. B.; Thomas, G. V.; Roberts, R. L.; Herbert, R.; Ittmann, M. M.; Rubin, M. A.; Humphrey, P. A.; Sundberg, J. P.; Rozengurt, N.; Barrios, R.; Ward, J. M.; Cardiff, R. D.
  3. Cancer Research. 2004 64(6): 2270-2305.
  1. 23.   Excitations, optical absorption spectra, and optical excitonic gaps of heterofullerenes. 1. C-60, C59N+, and C48N12: Theory and experiment
  2. Xie, R. H.; Bryant, G. W.; Sun, G. Y.; Nicklaus, M. C.; Heringer, D.; Frauenheim, T.; Manaa, M. R.; Smith, V. H.; Araki, Y.; Ito, O.
  3. Journal of Chemical Physics. 2004 120(11): 5133-5147.
  1. 24.   The hollow fibre model in cancer drug screening: the NCI experience
  2. Decker, S.; Hollingshead, M.; Bonomi, C. A.; Carter, J. P.; Sausville, E. A.
  3. European Journal of Cancer. 2004 40(6): 821-826.
  1. 25.   Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity
  2. Jansen, A. P.; Camalier, C. E.; Stark, C.; Colburn, N. H.
  3. Molecular Cancer Therapeutics. 2004 3(2): 103-110.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel